Modulatory mechanisms in the isolated internally perfused ventricle of the whelk Busycon canaliculatum

1. Isolated cannulated ventricles commenced spontaneous beating on application of perfusion pressure of 10 cm water. Complete hearts showed a fast patterned cyclical rhythm, whereas ventricles devoid of atrial material showed a continuous slow rhythm. 2. Perfused ventricles were inhibited by ACh with a threshold at 10(-8) mol l-1 and arrested at 10(-7) mol l-1, and ventricles under stimulation by 5HT could be arrested by ACh at this concentration. 3. Perfused ventricles were stimulated by 5HT, with threshold at 10(-9) mol l-1 and maximum at 10(-5) mol l-1. Metoclopramide was without affect on 5HT responses, but metitipine and methysergide did inhibit such responses suggesting that the 5HT receptor present possessed mixed properties of the vertebrate 5-HT1 and 5-HT2 receptor subtypes. 4. Ventricles were very sensitive to the excitatory actions of FMRFamide in the 10(-9) to 10(-5) mol l-1 range. Preparations were insensitive to GAPFLRFamide, but SCP-B was modestly excitatory (threshold 10(-7) mol l-1). 5. Preparations were not significantly affected by adenosine, ATP, and guanosine, but GTP was strongly excitatory at 10(-7) mol l-1. 6. 5HT and FMRFamide responses were additive. Preparations responded strongly to the adenylate cyclase activator forskolin and dibutyryl cAMP enhanced spontaneous contractions and 5HT responses, suggesting that the 5HT receptor may operate via a cAMP secondary mechanism. 7. The IP3 inhibitor lithium (10 mmol l-1), caused slight inhibition of FMRFamide responses, suggesting that the receptor to this peptide may operate via IP3 as a second messenger. 8. Neuromodulation in this preparation would appear to involve ACh as inhibitor, 5HT and FMRFamide as upregulators, with no clear roles for FMRFamide-related peptides and GTP.     

Imaging of nodal metastases in the head and neck

Therapeutic outcome of head and neck cancer is influenced strongly by the presence of nodal metastases. Sensitivity and specificity of the physical examination for the diagnosis of nodal metastasis is unsatisfactory, resulting in both false negatives and false positives of 25 to 40%. Preoperative detection of nodal metastases therefore becomes one of the important goals of imaging studies of patients with head and neck cancer. Despite several advanced techniques and the wide clinical use of MR, MR has surprisingly added little to the diagnostic accuracy of contrast-enhanced CT. Although CT and MR allow detection of abnormally enlarged nodes or necrotic nodes, neither borderline-sized nodes without necrosis nor extracapsular spread are reliably differentiated from reactive or normal nodes in patients with head and neck cancer. Lack of definitive diagnostic methods of metastatic lymph nodes is a serious shortcoming in the preoperative workup for patients with head and neck cancer. To avoid missing small metastatic nodes, a large number of patients clinically staged as N0 have undergone elective neck dissection to exclude metastases. With development of more tissue-specific imaging techniques, patients can be better characterized according to the status of nodal disease so that an appropriate therapeutic protocol can be designed for an individual case.     

Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline

Evolution of HIV-1 env sequences was studied in 15 seroconverting injection drug users selected for differences in the extent of CD4 T cell decline. The rates of increase of either sequence diversity at a given visit or divergence from the first seropositive visit were both higher in progressors than in nonprogressors. Viral evolution in individuals with rapid or moderate disease progression showed selection favoring nonsynonymous mutations, while nonprogressors with low viral loads selected against the nonsynonymous mutations that might have resulted in viruses with higher levels of replication. For 10 of the 15 subjects no single variant predominated over time. Evolution away from a dominant variant was followed frequently at a later time point by return to dominance of strains closely related to that variant. The observed evolutionary pattern is consistent with either selection against only the predominant virus or independent evolution occurring in different environments within the host. Differences in the level to which CD4 T cells fall in a given time period reflect not only quantitative differences in accumulation of mutations, but differences in the types of mutations that provide the best adaptation to the host environment.     

Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229)

PURPOSE: The primary objectives of the study were to evaluate the efficacy and safety of prolonged oral (PO) etoposide as part of cisplatin-based chemotherapy plus concurrent chest/brain irradiation induction, followed by CAV consolidation, in the treatment of patients with limited-stage small cell lung cancer (SCLC-LD) within a cooperative group setting. METHODS AND MATERIALS: Fifty-six eligible patients with SCLC-LD received three 28-day cycles of cisplatin 50 mg/m2 i.v. (days 1, 8; 29, 36; and 57, 64), PO etoposide 50 mg/m2 (days 1-14, 29-42, and 57-70), and vincristine 2 mg i.v. (days 1, 29, and 57). Thoracic irradiation (TRT) was administered at 1.8 Gy in 25 daily fractions to a total dose of 45 Gy via an AP:PA arrangement, to begin concomitantly with induction chemotherapy. Prophylactic cranial irradiation (PCI) was started on day 15 of induction therapy. Fifteen daily fractions of 2.0 Gy were administered to the entire brain to a total dose of 30 Gy to finish at approximately the same time as TRT. Two 21-day cycles of consolidation cyclophosphamide 750 mg/m2 i.v., doxorubicin 50 mg/m2 i.v., and vincristine 2 mg i.v. (all on days 1 and 22), were given beginning on day 106 or week 16, from the start of induction therapy. RESULTS: Among 56 eligible patients, 93% had SWOG performance status 0-1. All had adequate organ function and had not received prior therapy. The overall confirmed response rate was 46%, including 16% complete responders and 30% partial responders. After a minimum follow-up duration of 17 months, the Kaplan-Meier median progression-free (PFS) and overall survival (OS) were 10 and 15 months, respectively. Two-year survival is 28%. Only 28 of 56 patients (50%) completed chemotherapy per protocol, while 52 of 56 patients (93%) completed radiation per protocol. Eleven patients (20%) discontinued secondary to toxicity and two patients died from treatment. The major toxicity was hematologic. The two deaths were secondary to infection. Of the nonhematologic toxicities, there were 10 cases of pulmonary fibrosis (including one Grade 3) and six cases of pneumonitis (including one Grade 3). CONCLUSION: Concomitant chemoradiation with oral etoposide as part of a platinum-based chemotherapy and TRT induction regimen is toxic. The CR rate is not better than our prior best group-wide experience. The progression-free and overall survival are similar to published trials utilizing short-course i.v. etoposide. As in chemotherapy for extensive-stage SCLC, there is no apparent advantage to prolonged exposure to etoposide, and toxicity resulted in an inferior therapeutic index compared to programs with shortened exposure.     

25 years of aortic valve replacement using mechanical valves. Risk factors for early and late mortality

This study describes the changes that have taken place in patient characteristics in 25 years of aortic valve replacement using mechanical valves, and looks for risk factors for early and late mortality. During this period, 1449 mechanical valves were implanted. Overall early mortality (< 30 days) was 5.3% and for aortic valve replacement without concomitant procedures 3.9%. Overall survival rates at 5, 10 and 15 years were 80%, 63% and 49%, respectively. Despite an increased proportion of higher risk patients (older age, more reoperations, more concomitant coronary bypass surgery) survival rates improved throughout the study period. Early mortality was related to an early year of operation, urgency, reoperation and concomitant surgery to the tricuspid valve or ascending aorta. Late mortality was higher for patients of older age, with an early year of operation, male gender, concomitant coronary bypass surgery, mitral valve surgery or replacement of the ascending aorta. Aortic regurgitation did not have a major influence on early nor late mortality. The improvement in early and late mortality in more recent years was largely the result of the introduction of cardioplegia. A changing, non-proportional effect was observed for several risk factors during the follow-up period. This study illustrates the changes and improvements in medical care that have taken place in patients requiring aortic valve replacement.